Skip to main content
Erschienen in: Cancer Imaging 1/2017

Open Access 01.12.2017 | Research

Lymphomatosis cerebri: a rare variant of primary central nervous system lymphoma and MR imaging features

verfasst von: Hui Yu, Bo Gao, Jing Liu, Yong-Cheng Yu, Mark S. Shiroishi, Ming-Ming Huang, Wen-Xiu Yang, Zhi-Zhong Guan

Erschienen in: Cancer Imaging | Ausgabe 1/2017

Abstract

Background

Lymphomatosis cerebri (LC) is a rare variant of primary central nervous system lymphoma (PCNSL), characterized by diffuse infiltration without the formation of a discrete mass. The diagnosis of LC is a challenge because the imaging findings are atypical for lymphoma. The purpose of present study is to investigate MRI characteristics and clinical features of LC and potentially facilitate an early and accurate diagnosis of this often-missed disease.

Methods

Seven patients (average 44 years, 19–58 years) with LC proved basing on MRI and histology were retrospectively reviewed the clinical data and cerebral MR imaging findings.

Results

The common presenting symptoms were cognitive decline, behavioral disturbance, gait disturbance. All patients had both deep and lobar lesion distribution, and two of them had infratentorial involvement. Lack of contrast enhancement and subtle patchy enhanced pattern were observed in two and three patients, respectively. The remaining two patients presented multiple patchy enhancement. Most of the lesions were slightly hyperintense to normal brain on DWI as well as hyperintense on ADC maps. Three patients presented a pattern of marked decrease of NAA/Cr, increase of Cho/Cr, and two of the three cases showed increased Lip/Cr and Lac/Cr on MRS.

Conclusions

We conclude that diffuse bilateral lesions especially in deep and lobar region including white and gray matter, without enhancement or with patchy enhancement, marked decrease of NAA/Cr and increase of Cho/Cr, and increased Lip/Cr and Lac/Cr are suggestive of LC. Prompt recognition of these imaging patterns may lead to early diagnosis of LC and brain biopsy with improved prognosis.
Abkürzungen
ADC
Apparent diffusion coefficient
BBB
Blood-brain barrier
Cho
Choline
CNS
Central nervous system
Cr
Creatine
DPWM
Deep and periventricular white matter
DTI
Diffusion tensor imaging
DWI
Diffusion-weighted imaging
FLAIR
Fluid attenuated inversion recovery
HE
Hematoxylin-eosin staining
Lac
Lactate
LC
Lymphomatosis cerebri
Lip
Lipid
MRS
Magnetic resonance spectroscopy
NAA
N-acetylaspartate
PCNSL
Primary central nervous system lymphoma

Background

Lymphomatosis cerebri (LC) is a rare variant of primary central nervous system lymphoma (PCNSL), characterized by diffuse infiltration without the formation of a discrete mass and with little contrast enhancement [1], appearing similar to gliomatosis cerebri [2]. This uncommon entity is a diagnostic challenge because the clinical presentation is subacute and the imaging findings are very different from other PCNSLs which typically presents as single or multiple T2-hyperintense, nodular contrast-enhancing mass lesions on MRI [1]. Central nervous system infections, inflammatory, toxic, and metabolic disorders can also mimic the radiologic features of LC [3, 4]. Therefore, early and accurate diagnosis of LC could be crucial for its appropriate treatment choices [5]. Besides traditional MRI, diffusion weighted imaging (DWI) and magnetic resonance spectroscopy (MRS) can also be informative and useful for diagnosis of this rare disease. Neuroimaging studies of LC are rare, and the characteristics of MRI findings remain to be fully elucidated. This study was designed to retrospectively analyze the MRI and clinical manifestations of 7 patients with histopathologically confirmed LC. This summary of the MRI features of LC may facilitate early diagnosis and intervention of this often-missed disease.

Case presentation

Patients and methods

We retrospectively reviewed the clinical data and cerebral MR imaging of 7 patients (from January 2012 to December 2016)who were diagnosed basing on the following criteria: (i) presence of diffuse lesions in the brain MRI without contrast enhancement or with patchy contrast enhancement and (ii) histology revealing lymphoma. Patients with concurrent systemic lymphoma and intravascular lymphoma were excluded. All the patients underwent stereotactic brain biopsy and were diagnosed with lymphoma by two experienced neuropathologists (each with 7 and 15 years of experience, respectively) according to hematoxylin-eosin (H&E) staining and immunohistochemical examinations. All patients provided informed consent for MRI examination and for the use of personal data.
MRIs of three patients were performed on 3.0 Tesla Philips Achieva(Netherlands) scanner, three other cases were imaged on a 1.5 Tesla Siemens Magnetom Avanto(Germany), one patient was imaged on 1.5 Tesla GE(America). All patients had T2-weighted fluid attenuated inversion recovery(FLAIR), T2- and T1-weighted images. Post-contrast T1-weighted images were available for all patients after intravenous administration of 0.1 mmol/kg gadopentetate dimeglumine(Beilu Inc.). DWI was available in 5 patients, while MRS was available in 3 patients. The DWI was obtained using B-values of 0, 1000 s/mm2. The mean ADC values in the lesions and in normal-appearing white matter were measured by two experienced neuroradiologists (each with 7 and 15 years of experience, respectively). MR spectroscopy was performed with a intermediate echo time (135 ms or 40 ms) as multi-voxel or single-voxel 2D exam encompassing the lesion. For MRS, the major metabolites(Choline (Cho), N-acetylaspartate (NAA) and Creatine (Cr)) were determined. Also, the presence of lipids(Lip) and lactate(Lac) peaks was determined. For each spectrum, the peak height of total creatine (Cr) was used as the internal reference to quantify other metabolites.
The two neuroradiologists, who were blinded to patient data, reviewed and analyzed the cerebral MRI in consensus. All scans were reviewed noting lesions location in the brain, patterns of contrast enhancement, the signal of DWI and corresponding ADC map, and MRS metabolic patterns. The lesions distribution were classified into deep, lobar, and infratentorial categories(Type I,II and III respectively). Deep regions included the basal ganglia, thalamus, internal capsule, external capsule, corpus callosum, and deep and periventricular white matter (DPWM); lobar regions included cortical gray matter and subcortical regions(including lateral white matter adjacent to DPWM); infratentorial regions included the brainstem and cerebellum. DPWM was defined as white matter adjacent to or within approximately 10 mm of the lateral ventricular margin. Contrast enhancement was defined as patchy when a minimally or moderately heterogeneous, not well-defined area of contrast enhancement was present, regardless of size. The criterion for diffusion restriction lesions was hyperintense areas on DWI with corresponding hypointensity on the ADC map. Disagreements were resolved by consensus.

Results

Our case series was composed of 3 men and 4 women, ranging from 19 to 58 years of age (average year is 44 and medium year is 49). Presenting symptoms were cognitive decline in 4, behavioral disturbance in 2, gait disturbance in 2, coma in 1 and altered level of consciousness in 1 patient. Five patients were diagnosed with diffuse large B-cell lymphoma and two patients had T-cell lymphoma. One patient was treated with corticosteroids and died 1 month after the biopsy. After courses of chemotherapy in remaining 6 patients, there was some neurological and radiological improvement in four cases, but one patient died 9 months after the biopsy and another one patient appeared a mass lesion in parietal lobe after six courses of chemotherapy.
Patient demographics, cerebral MRI findings and pathological types are summarized in Table 1. Representative FLAIR, pre-contrast T1WI and post-contrast T1WI, available DWI and ADC maps, available MRS are shown in Figs. 1, 2, 3, 4 and 5. All patients had both deep and lobar lesion distribution, and two of them had infratentorial involvement. Lack of contrast enhancement and subtle patchy enhanced pattern were observed in two and three patients, respectively. The remaining two patients presented multiple patchy enhancement. Most of the lesions were slightly hyperintense to normal brain on DWI as well as hyperintense on ADC maps, which were consistent with the increasing diffusivity. Two cases showed increased peak of Lip and Lac on MRS. The pathology was characterized by dispersed round neoplastic cells spreading along the white matter tracts without causing tissue destruction or mass formation and was occasionally clustered around blood vessels (Fig. 6 A). Five cases were strongly labeled CD20, a B cell marker (Fig. 6 B) and two cases were positive for CD3, consistent with T-cell lymphoma.
Table 1
MRI features of the LC cases and histological diagnosis
Case
Sex/Age (years)
Types of lesions distribution
Enhancement
DWI
1H–MRS
Pathological type
I
II
III
    
1
M/55
“+”
“+”
“+”
Multiple patchy
Slightly hyperintense
 
B
2
F/49
“+”
“+”
 
Partial patchy
NE
 
B
3
F/45
“+”
“+”
 
Partial patchy
Slightly hyperintense
Cho/Cr ↑ NAA/Cr↓ Lac/Cr ↑
B
4
F/57
“+”
“+”
 
Partial patchy
Slightly hyperintense
 
B
5
M/27
“+”
“+”
 
Multiple patchy
Slightly hyperintense
Cho/Cr ↑ NAA/Cr↓ Lip/Cr ↑
T
6
M/19
“+”
“+”
“+”
No
Slightly hyperintense
Cho/Cr ↑ NAA/Cr↓
T
7
F/58
“+”
“+”
 
No
NE
 
B
LC lymphomatosis cerebri, NE not evaluated, DWI diffusion-weighted imaging, MRS magnetic resonance spectroscopy, Cho choline, Lip Lipid, Lac lactate, NAA N-acetylaspartate, Cr creatine, B diffuse large B-cell lymphoma, T, T-cell lymphoma

Discussion

About 90% of PCNSL’s are diffuse large B-cell lymphomas and only 5% constitute low-grade B-cell type lymphoma, including mucosa-associated lymphoid tissue type and T-cell type lymphoma [6]. LC is a rare type of CNS lymphoma characterized by lymphoma cells diffusely infiltrating the brain parenchyma without forming a mass or distorting the cerebral architecture [2]. MR imaging typically reveals diffuse white matter disease variably involving bilateral cerebral hemispheres, periventricular region, basal ganglia, thalami, or the brainstem [1]. With the aim of improving knowledge of this entity, we documented the clinical features and brain MR imaging findings from 7 patients with LC and analyzed the abnormal findings of multiparametric MRI focusing on: 1) distribution of lesions on conventional MRI, 2) patterns of contrast enhancement, 3) signal of DWI, and 4) metabolite changes on MRS.

Clinical features

Patients with LC may have variable clinical symptoms such as gait disturbance, focal weakness, decline of cognitive function, memory disturbance, personality changes, dementia, anorexia, orthostatic hypotension, paraparesis and weight loss [3]. Of these, the most common presenting symptoms are cognitive decline(59.5%), gait disturbances(54.8%) and behavioral changes(50%) [5]. Similar to most reported cases presented with rapidly progressing dementia accompanied by extensive leukoencephalopathy on MRI [2, 7, 8], four of our cases were typical of previously described LC cases. But the clinical presentation of these patients were easily mistaken for other, more common, conditions such as infectious, inflammatory, vascular, toxic, or neurodegenerative etiologies that can cause white-matter injury. Our cases suggested that it is important for clinicians to be aware of this LC form of PCNSL and LC should be added to the differential diagnosis of cognitive decline.

Distribution of lesions

It is noteworthy that all the patients had bilateral hemispheric lesions on MRI. Conventional MRI without contrast enhancement showed extensive, diffuse hyperintense lesions involving bilateral cerebral hemispheres on both T2-weighted FLAIR sequences. Case 1 and 6 of our series had concurrent infratentorial and supratentorial infiltration. The remaining patients presented with isolated supratentorial infiltration. The most common regions involved were the white matter of both hemispheres, in the frontal and deep periventricular regions including corpus callosum, and the lesions extended into the gray matter such as basal ganglia,thalamus and cortex. We classified these lesions by distribution into deep, lobar, and infratentorial categories as TypeI,II and III, respectively. The two most common lesion distribution in LC included those in the deep and lobar categories regardless if the lesions involved gray or white matter. The lesions of deep brain regions type were always bilateral and incompletely symmetrical distribution in LC, but the lesions of lobar type were always unilateral. Lymphomatous cells have a tendency to traffic in rows between white matter fibers rather than expanding diffusely [9]. The diffuse findings can be explained by the theory that lymphoma has to be considered as a whole brain disease even when it presents with a cohesive mass [10].
Given the multifocal distribution of the lesions in white matter, the main differential considerations were Binswanger’s disease(subcortical ischemic vascular dementia), infectious leukoencephalitis, toxic encephalopathy, or neoplasms such as gliomatosis cerebri [2, 1113]. However, diffuse involvement of both hemispheres and incompletely symmetrical distribution, including involved white matter and deep gray matter simultaneously, distinguish LC from other entities considered in the differential diagnosis.

Patterns of contrast enhancement

Most patients of our series showed patchy contrast enhancement. Bakshi et al. [2] defined cases of LC as diffuse white matter infiltration without the formation of discrete mass lesions and with little contrast enhancement. Rollinset al. [12]reviewed the pathological findings of LC. In LC, there is a diffuse pattern of brain infiltration coupled with the associated perivascular cuffing by both lymphoma cells and non-neoplastic lymphocytes that can mimic an encephalitic pattern [2]. The common reason for a lack of contrast enhancement on MRI is assumed to be an intact blood-brain barrier (BBB), or that significant BBB disruption by lymphoma cells is not yet produced [14]. However, subtle or patchy contrast enhancement has been described in some cases [6, 7]. In these cases, biopsy revealed tumor cells that induced subtle contrast enhancement distributed throughout the white matter; the atypical cells were neither cohesive nor did they form a mass [3]. Subtle patchy contrast enhancement was found in 3 of our 7 patients and 2 patients showed multiple patchy. Our Case 5 showed more substantial contrast enhancement in both cerebral hemispheres, which was misdiagnosed with encephalitis based on the initial MRI and improved after steroid treatment. Histopathological analysis of this patient revealed severe tumor cell infiltration with small round lymphatic cells cuffing and destroying microvasculature, which is consistent with the imaging finding of multi-focal patchy contrast enhancement due to BBB disruption. Delayed scanning post-contrast T1WI was 20 min after the initial scan and showed marked contrast enhancement (Figure 3). Other reports [4, 15] have reported that contrast enhancement patterns can change in LC patients on follow-up MRI. A systematic review LC patients found that 26.6% of those without contrast enhancement on the initial MRI and 16.6% of those who showed patchy contrast enhancement eventually developed nodular contrast enhancing lesions at follow-up imaging [5]. The transformation from a non-enhancing to enhancing lesion reflects the eventual disruption of the BBB [16]; this is likely a late event that is due to factors at the cellular level [17]. Although the reason for this transformation remains unclear, we speculate that LC without contrast enhancement might be an early-stage appearance of this specific type of PCNSL with diffuse infiltrating neoplastic cells.

Diffusion weighted imaging

DWI reflects the motion of intra- and extra-cellular water. It is helpful in distinguishing between PCNSL and other tumors and tumor-mimicking lesions [18]. Highly cellular tumors, like central nervous system(CNS) lymphoma, generally present as single or multiple contrast-enhancing mass lesions on MRI scans, with hyperintensity on DWI and hypointensity on ADC maps [19]. Decreased ADC value suggests increased cellularity [20].We observed subjective diffusion restriction in portions of the lesions in two cases, suggesting high cellularity in these portions of the lesions. But most of the lesions were slightly hyperintense to normal brain on DWI and hyperintense on ADC maps, consistent with increased diffusivity. The hyperintensity on DWI and hyperintensity on ADC map may have reflect diffuse cerebral infiltration of non-cohesive malignant lymphoid cells and T2 shine-through effect. Histopathological analysis revealed blastic lymphocytic cells with large pleomorphic nuclei and distinct nucleoli diffusely infiltrating the parenchyma. These lymphocytes showed the typical angiocentric infiltration pattern, and tumor cells invaded the neural parenchyma with a diffuse growth pattern from these perivascular cuffs. Although DWI was not suggestive of LC in our cases, the variation of DWI signal intensity may be a reflection of the variation of tumor cellular density. However, the slight DWI hyperintensity is difficult to differentiate from gliomatosis cerebri, infectious leukoencephalitis, and toxic encephalopathy.

MR spectroscopy(MRS)

MRS allows for the semiquantitative in-vivo evaluation of metabolites, such as NAA, Cho, Cr, Lac, and Lip. In PCNSL,MRS has demonstrated elevated Lip and Lac peaks, high Cho/Cr ratios, decreased NAA levels and high Cho/NAA ratios [21, 22]. PCNSL grows rapidly and behaves similar to other high-grade brain tumors with evidence of high cell membrane turnover on MRS(high Cho peak), neuronal damage (decreased NAA levels), and anaerobiosis (high lactate levels) [18, 19, 22].These findings are similar to those for high-grade gliomas and metastases; however, MRS is useful to suggest PCNSL because lipids were found to be useful to discriminate between PCNSL and glioblastoma/metastasis at short TE [23].In our three LC patients, MRS (at TE 135 ms or 40 ms) consistently presented a pattern of marked decrease of NAA/Cr, increase of Cho/Cr, which is suggestive of malignant neoplastic disease. Two patients showed increased Lip/Cr and Lac/Cr. The presence of this MRS pattern may help in the differential diagnosis of brain non-neoplastic diseases [20]. We determined that MRS is potentially useful to reinforce the suspicion of LC when bilateral hemispheric lesions were found on an MRI exam. Although LC is a relatively rare type of PCNSL, establishing suspicion of LC by imaging could be a pivotal step in determining management strategies for patients, as it would result in a consideration of biopsy before initiation of treatment with steroids [23].

Limitations

There are several limitations in this study. First, LC is rare and the cases came from multiple institutions. As a result, we had a small sample size and heterogeneity of the dataset where DWI and MRS were not available in all cases; variable imaging sequences were performed in each case. Other advanced imaging techniques were also not available for these challenging cases, including MR perfusion and diffusion tensor imaging (DTI). Perfusion MRI can improve the diagnostic accuracy of PCNSL, particularly when the brain parenchyma is affected [24]. DTI takes advantage of highly ordered white matter fibers, and the FA values for PCNSL can help in the differentiation of glioblastoma [25].

Conclusion

In conclusion, it is important for clinicians and radiologists to be aware of the LC form of PCNSL. Diffuse bilateral lesions especially in deep and lobar region including white and gray matter, without enhancement or with patchy enhancement, marked decrease of NAA/Cr and increase of Cho/Cr, and increased Lip/Cr and Lac/Cr are suggestive of LC. Prompt recognition of these imaging patterns may lead to early diagnosis of LC and brain biopsy with improved prognosis.

Acknowledgements

We thank all surgeons and neurologists who contributed to patients’ management.

Funding

Collection, interpretation of data and writing manuscript were supported by Chinese National Natural Science Foundation GR-81260173,Guizhou Provincial Education Department KY[2016]012, SC CTSI (NIH/NCRR/NCATS) GR-KL2TR000131 and NIH 1 L30 CA209248–01.

Availability of data and materials

The datasets during and/or analyzed during the current study available from the corresponding author on reasonable request.
All patients provided an informed consent for MRI examination and for the use of personal data. Therefore, for this retrospective analysis ethics committee approval was not requested. All data, including images, were anonymized and all patients provided their consent for the use of personal data.
All the patients have given a written consent to use their data for research purpose, including publications in medical journals.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Hatanpaa KJ, Fuda F, Koduru P, Young K, Lega B, Chen W. Lymphomatosis Cerebri: A Diagnostic Challenge. JAMA Neurol. 2015;72:1066–7.CrossRefPubMed Hatanpaa KJ, Fuda F, Koduru P, Young K, Lega B, Chen W. Lymphomatosis Cerebri: A Diagnostic Challenge. JAMA Neurol. 2015;72:1066–7.CrossRefPubMed
2.
Zurück zum Zitat Bakshi R, Mazziotta JC, Mischel PS, Jahan R, Seligson DB, Vinters HV. Lymphomatosis cerebri presenting as a rapidly progressive dementia: clinical, neuroimaging and pathologic findings. Dement Geriatr Cogn Disord. 1999;10:152–7.CrossRefPubMed Bakshi R, Mazziotta JC, Mischel PS, Jahan R, Seligson DB, Vinters HV. Lymphomatosis cerebri presenting as a rapidly progressive dementia: clinical, neuroimaging and pathologic findings. Dement Geriatr Cogn Disord. 1999;10:152–7.CrossRefPubMed
3.
Zurück zum Zitat Kitai R, Hashimoto N, Yamate K, Ikawa M, Yoneda M, Nakajima T, Arishima H, Takeuchi H, Sato K, Kikuta K. Lymphomatosis cerebri: clinical characteristics, neuroimaging, and pathological findings. Brain Tumor Pathol. 2012;29:47–53.CrossRefPubMed Kitai R, Hashimoto N, Yamate K, Ikawa M, Yoneda M, Nakajima T, Arishima H, Takeuchi H, Sato K, Kikuta K. Lymphomatosis cerebri: clinical characteristics, neuroimaging, and pathological findings. Brain Tumor Pathol. 2012;29:47–53.CrossRefPubMed
4.
Zurück zum Zitat Lewerenz J, Ding XQ, Matschke J, Schnabel C, Emami P, von Borczyskowski D, Buchert R, Krieger T, de Wit M, Munchau A. Dementia and leukoencephalopathy due to lymphomatosis cerebri. BMJ Case Rep. 2009;2009 10.1136/bcr.08.2008.0752. Lewerenz J, Ding XQ, Matschke J, Schnabel C, Emami P, von Borczyskowski D, Buchert R, Krieger T, de Wit M, Munchau A. Dementia and leukoencephalopathy due to lymphomatosis cerebri. BMJ Case Rep. 2009;2009 10.​1136/​bcr.​08.​2008.​0752.
5.
Zurück zum Zitat Izquierdo C, Velasco R, Vidal N, Sanchez JJ, Argyriou AA, Besora S, Graus F, Bruna J. Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. Neuro-Oncology. 2016;18:707–15.CrossRefPubMed Izquierdo C, Velasco R, Vidal N, Sanchez JJ, Argyriou AA, Besora S, Graus F, Bruna J. Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. Neuro-Oncology. 2016;18:707–15.CrossRefPubMed
6.
Zurück zum Zitat Sugino T, Mikami T, Akiyama Y, Wanibuchi M, Hasegawa T, Mikuni N. Primary central nervous system anaplastic large-cell lymphoma mimicking lymphomatosis cerebri. Brain Tumor Pathol. 2013;30:61–5.CrossRefPubMed Sugino T, Mikami T, Akiyama Y, Wanibuchi M, Hasegawa T, Mikuni N. Primary central nervous system anaplastic large-cell lymphoma mimicking lymphomatosis cerebri. Brain Tumor Pathol. 2013;30:61–5.CrossRefPubMed
7.
Zurück zum Zitat Raz E, Tinelli E, Antonelli M, Canevelli M, Fiorelli M, Bozzao L, Di Piero V, Caramia F. MRI findings in lymphomatosis cerebri: description of a case and revision of the literature. J Neuroimaging. 2011;21:e183–6.CrossRefPubMed Raz E, Tinelli E, Antonelli M, Canevelli M, Fiorelli M, Bozzao L, Di Piero V, Caramia F. MRI findings in lymphomatosis cerebri: description of a case and revision of the literature. J Neuroimaging. 2011;21:e183–6.CrossRefPubMed
8.
Zurück zum Zitat Weaver JD, Vinters HV, Koretz B, Xiong Z, Mischel P, Kado D. Lymphomatosis cerebri presenting as rapidly progressive dementia. Neurologist. 2007;13:150–3.CrossRefPubMed Weaver JD, Vinters HV, Koretz B, Xiong Z, Mischel P, Kado D. Lymphomatosis cerebri presenting as rapidly progressive dementia. Neurologist. 2007;13:150–3.CrossRefPubMed
9.
Zurück zum Zitat Vital A, Sibon I. A 64-year-old woman with progressive dementia and leukoencephalopathy. Brain Pathol. 2007;17:117–8. 121CrossRefPubMed Vital A, Sibon I. A 64-year-old woman with progressive dementia and leukoencephalopathy. Brain Pathol. 2007;17:117–8. 121CrossRefPubMed
10.
Zurück zum Zitat Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002;59:1557–62.CrossRefPubMed Lai R, Rosenblum MK, DeAngelis LM. Primary CNS lymphoma: a whole-brain disease? Neurology. 2002;59:1557–62.CrossRefPubMed
11.
Zurück zum Zitat Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med. 2001;345:425–32.CrossRefPubMed Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med. 2001;345:425–32.CrossRefPubMed
12.
Zurück zum Zitat Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, Damek DM, Filley CM. Lymphomatosis cerebri as a cause of white matter dementia. Hum Pathol. 2005;36:282–90.CrossRefPubMed Rollins KE, Kleinschmidt-DeMasters BK, Corboy JR, Damek DM, Filley CM. Lymphomatosis cerebri as a cause of white matter dementia. Hum Pathol. 2005;36:282–90.CrossRefPubMed
13.
Zurück zum Zitat Lewerenz J, Ding X, Matschke J, Schnabel C, Emami P, von Borczyskowski D, Buchert R, Krieger T, de Wit M, Munchau A. Dementia and leukoencephalopathy due to lymphomatosis cerebri. J Neurol Neurosurg Psychiatry. 2007;78:777–8.CrossRefPubMedPubMedCentral Lewerenz J, Ding X, Matschke J, Schnabel C, Emami P, von Borczyskowski D, Buchert R, Krieger T, de Wit M, Munchau A. Dementia and leukoencephalopathy due to lymphomatosis cerebri. J Neurol Neurosurg Psychiatry. 2007;78:777–8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Terae S, Ogata A. Nonenhancing primary central nervous system lymphoma. Neuroradiology. 1996;38:34–7.CrossRefPubMed Terae S, Ogata A. Nonenhancing primary central nervous system lymphoma. Neuroradiology. 1996;38:34–7.CrossRefPubMed
15.
16.
Zurück zum Zitat Samani A, Davagnanam I, Cockerell OC, Ramsay A, Patani R, Chataway J. Lymphomatosis cerebri: a treatable cause of rapidly progressive dementia. J Neurol Neurosurg Psychiatry. 2015;86:238–40.CrossRefPubMed Samani A, Davagnanam I, Cockerell OC, Ramsay A, Patani R, Chataway J. Lymphomatosis cerebri: a treatable cause of rapidly progressive dementia. J Neurol Neurosurg Psychiatry. 2015;86:238–40.CrossRefPubMed
18.
Zurück zum Zitat da Rocha AJ, Sobreira Guedes BV, da Silveira da Rocha TM, Maia Junior AC, Chiattone CS. Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis. Rev Bras Hematol Hemoter. 2016;38:44–54.CrossRefPubMed da Rocha AJ, Sobreira Guedes BV, da Silveira da Rocha TM, Maia Junior AC, Chiattone CS. Modern techniques of magnetic resonance in the evaluation of primary central nervous system lymphoma: contributions to the diagnosis and differential diagnosis. Rev Bras Hematol Hemoter. 2016;38:44–54.CrossRefPubMed
19.
Zurück zum Zitat Zacharia TT, Law M, Naidich TP, Leeds NE. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging. 2008;18:411–7.CrossRefPubMed Zacharia TT, Law M, Naidich TP, Leeds NE. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. J Neuroimaging. 2008;18:411–7.CrossRefPubMed
20.
Zurück zum Zitat Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32:984–92.CrossRefPubMed Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011;32:984–92.CrossRefPubMed
21.
Zurück zum Zitat Taillibert S, Guillevin R, Menuel C, Sanson M, Hoang-Xuan K, Chiras J, Duffau H. Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neuro-Oncol. 2008;86:225–9.CrossRef Taillibert S, Guillevin R, Menuel C, Sanson M, Hoang-Xuan K, Chiras J, Duffau H. Brain lymphoma: usefulness of the magnetic resonance spectroscopy. J Neuro-Oncol. 2008;86:225–9.CrossRef
22.
Zurück zum Zitat Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian KL. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neuro-Oncol. 2005;71:173–80.CrossRef Raizer JJ, Koutcher JA, Abrey LE, Panageas KS, DeAngelis LM, Lis E, Xu S, Zakian KL. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. J Neuro-Oncol. 2005;71:173–80.CrossRef
23.
Zurück zum Zitat Mora P, Majos C, Castaner S, Sanchez JJ, Gabarros A, Muntane A, Aguilera C, Arus C. (1)H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery. Eur Radiol. 2014;24:2895–905.CrossRefPubMed Mora P, Majos C, Castaner S, Sanchez JJ, Gabarros A, Muntane A, Aguilera C, Arus C. (1)H-MRS is useful to reinforce the suspicion of primary central nervous system lymphoma prior to surgery. Eur Radiol. 2014;24:2895–905.CrossRefPubMed
24.
Zurück zum Zitat Lee IH, Kim ST, Kim HJ, Kim KH, Jeon P, Byun HS. Analysis of perfusion weighted image of CNS lymphoma. Eur J Radiol. 2010;76:48–51.CrossRefPubMed Lee IH, Kim ST, Kim HJ, Kim KH, Jeon P, Byun HS. Analysis of perfusion weighted image of CNS lymphoma. Eur J Radiol. 2010;76:48–51.CrossRefPubMed
25.
Zurück zum Zitat Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, Wan YL. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol. 2008;29:471–5.CrossRefPubMed Toh CH, Castillo M, Wong AM, Wei KC, Wong HF, Ng SH, Wan YL. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. AJNR Am J Neuroradiol. 2008;29:471–5.CrossRefPubMed
Metadaten
Titel
Lymphomatosis cerebri: a rare variant of primary central nervous system lymphoma and MR imaging features
verfasst von
Hui Yu
Bo Gao
Jing Liu
Yong-Cheng Yu
Mark S. Shiroishi
Ming-Ming Huang
Wen-Xiu Yang
Zhi-Zhong Guan
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
Cancer Imaging / Ausgabe 1/2017
Elektronische ISSN: 1470-7330
DOI
https://doi.org/10.1186/s40644-017-0128-2

Weitere Artikel der Ausgabe 1/2017

Cancer Imaging 1/2017 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.